Patients reported a shortage of 6 billion rubles in the federal budget for 2025-27

The federal budget for 2025-2027 lacks almost 6 billion rubles to provide modern drugs for people with heart disease and high cholesterol (hypercholesterolemia), the All-Russian Patients Union (APU) has calculated. The organization proposed to allocate 1.8 billion rubles annually for these purposes.

According to the VSP, the allocation of additional funding will save the lives of almost 6 thousand people. So many patients with heart disease and hypercholesterolemia now live in Russia.

"Now innovative therapy, stabilizing the level of cholesterol in the blood, patients are forced to purchase at their own expense or it is purchased at the expense of regional budgets, but for this patients first need to pass the medical commission, which is not always on their side," - told "Izvestia" co-chairman of the VSP Yuri Zhulev.

According to him, the drugs in question are Praluent (active ingredient alirocumab), Repatha (everolokumab) and Sibrava (inclisiran). For each of the patients, Yuri Zhulev added, receiving modern therapy is practically the only chance to preserve life.

The patient organization also reported that the economic damage of hypercholesterolemia is almost 1.3 trillion rubles a year and noted that the allocation of additional funding for the purchase of modern drugs will reduce the burden on the health care system and reduce further government spending on such patients.

Read more in the exclusive material of Izvestia:

The course for treatment: heart patients lack 6 billion rubles from the budget